Literature DB >> 7730448

Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases.

L H Van den Berg1, I Mollee, J H Wokke, T Logtenberg.   

Abstract

We have used the HPRT mutant clonal assay to determine the frequency of mutant T lymphocytes (FMC), as a measure of recent T cell stimulation, in the blood of patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP). We found that, compared to healthy controls, the FMC in patients with GBS (16) and CIDP (10) was significantly increased in the progressive phase of the neuropathy. FMC returned to normal values during recovery, suggesting a relationship between FMC and disease activity. No correlation was found between FMC values and motor deficit or severity of the neuropathy. The FMC of the GBS patients with a history of infection before onset of neurological symptoms or with insufficient respiration was not significantly different from the other GBS patients. Immunophenotypic analysis showed that the fraction of CD8+ HPRT mutant T cell clones was significantly increased in GBS patients (48%) compared to healthy controls (3%) or CIDP patients (4.5%). Our results are compatible with the notion that T cells are involved in the pathogenesis of demyelinating inflammatory neuropathies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730448     DOI: 10.1016/0165-5728(94)00185-q

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

1.  In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells.

Authors:  Cindy L Zuleger; Michael D Macklin; Bret L Bostwick; Qinglin Pei; Michael A Newton; Mark R Albertini
Journal:  J Immunol Methods       Date:  2010-12-21       Impact factor: 2.303

2.  VIP-expressing dendritic cells protect against spontaneous autoimmune peripheral polyneuropathy.

Authors:  Mehmet E Yalvac; William David Arnold; Syed-Rehan A Hussain; Cilwyn Braganza; Kimberly M Shontz; Kelly Reed Clark; Christopher M Walker; Eroboghene E Ubogu; Jerry R Mendell; Zarife Sahenk
Journal:  Mol Ther       Date:  2014-04-25       Impact factor: 11.454

3.  Sixth nerve palsy from a CNS lesion in chronic inflammatory demyelinating polyneuropathy.

Authors:  J H Wokke; L H van den Berg; J P van Schaik
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 4.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Efficiency of long-term treatment with intravenous immunoglobulins correlates with reduced autoreactive T cell responses in chronic inflammatory demyelinating polyneuropathy patients.

Authors:  J Klehmet; C Meisel; A Meisel
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 6.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

7.  Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).

Authors:  C Hirst; S Raasch; G Llewelyn; N Robertson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06       Impact factor: 10.154

Review 8.  Molecular characterization of hypoxanthine guanine phosphoribosyltransferase mutant T cells in human blood: The concept of surrogate selection for immunologically relevant cells.

Authors:  Noah A Kaitz; Cindy L Zuleger; Peng Yu; Michael A Newton; Richard J Albertini; Mark R Albertini
Journal:  Mutat Res Rev Mutat Res       Date:  2022-03-11       Impact factor: 7.015

9.  Clonal expansions of 6-thioguanine resistant T lymphocytes in the blood and tumor of melanoma patients.

Authors:  Mark R Albertini; Michael D Macklin; Cindy L Zuleger; Michael A Newton; Stephen A Judice; Richard J Albertini
Journal:  Environ Mol Mutagen       Date:  2008-12       Impact factor: 3.216

Review 10.  The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Kathleen M Hagen; Shalina S Ousman
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.